ANDA 83666, held by Watson Labs. Hydrochlorothiazide; Reserpine.
As of Nov 16, 2026, ANDA 83666 (Hydrochlorothiazide W/ Reserpine), held by Watson Labs, was not approved, with 7 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrochlorothiazide W/ Reserpine50MG;0.125MG ยท tablet;oral | Hydrochlorothiazide; Reserpine | Discontinued |
| Nov 30, 1988 | Supplement 31Manufacturing | Approved | None posted |
| Aug 26, 1988 | Supplement 30Manufacturing | Approved | None posted |
| Mar 8, 1988 | Supplement 29Manufacturing | Approved | None posted |
| Dec 4, 1987 | Supplement 28Manufacturing | Approved | None posted |
| Feb 25, 1986 | Supplement 27Manufacturing | Approved | None posted |
| Dec 6, 1983 | Supplement 24Manufacturing | Approved | None posted |
| Mar 29, 1982 | Supplement 18Manufacturing | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters